Shire Faces Consumer Antitrust Claims Over Adderall

Law360, New York (April 2, 2013, 7:56 PM EDT) -- Consumers in Pennsylvania and Florida hit Shire US Inc. with a pair of putative class actions this week accusing the pharmaceutical company of illegally stifling competition for Adderall XR, its blockbuster treatment for attention deficit hyperactivity disorder, with patent settlements and supply agreements with generic rivals.

Both cases focus on so-called pay-for-delay settlements that Shire inked with generics makers Teva Pharmaceuticals USA Inc. and Impax Laboratories Inc. to resolve allegations that the two companies' efforts to market a generic version of Adderall would violate Shire's patents. Neither generic is named in either suit, though both complaints list unnamed John Doe defendants....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS